Healthy adults
Conditions
Interventions
100g beverage containing bifidobacterium GCL2505 (1.10^10 CFU/mL) and inulin (2g) (once a day for 4 weeks), observation period (3 weeks, post-treatment period (4 weeks)
100g placebo beverage containin
Sponsors
Ezaki Glico Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects whose defecation frequency is more than 5 times per week
Exclusion criteria
Exclusion criteria: 1. Subjects who regularly use intestinal and constipation drugs (including strong laxatives) 2. Subjects who are heavy drinkers or alcoholics. 3. Subjects who consume following foods (daily or during ingestion period): food containing lactic acid bacteria and bifidobacteria (fermented milk, beverages, supplement etc.,), prebiotics and oligosaccharides, food containing a large amount of dietary fiber (beverages, supplements etc.,) 4. Subjects who have a disease that requires emergency treatment, or have serious complications 5. Subjects who have a medical history of digestive diseases or surgeries affecting digestion and absorption 6. Subjects with food allergy 7. Subjects who are pregnant or plan to become pregnant , or breast-feeding during the study 8. Subjects who are participating in other clinical trials that intake/apply any foods or drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 16S rRNA gene based metagenome analysis of gut microbiome | — |
Secondary
| Measure | Time frame |
|---|---|
| fecal bifidobacteria fecal short-chain fatty acids | — |
Countries
Japan
Contacts
Public ContactTakashi Mawatari
Ezaki Glico Co., Ltd. Institute of Health Sciences
Outcome results
None listed